Rusnak JM - Search Results

1

Comparison of Aerosol- and Percutaneous-acquired Venezuelan Equine Encephalitis in Humans and Nonhuman Primates for Suitability in Predicting Clinical Efficacy under the Animal Rule.

Rusnak JM, Dupuy LC, Niemuth NA, Glenn AM, Ward LA. Rusnak JM, et al. Comp Med. 2018 Oct 1;68(5):380-395. doi: 10.30802/AALAS-CM-18-000027. Epub 2018 Oct 3. Comp Med. 2018. PMID: 30282570 Free PMC article.

2

Approach to Strain Selection and the Propagation of Viral Stocks for Venezuelan Equine Encephalitis Virus Vaccine Efficacy Testing under the Animal Rule.

Rusnak JM, Glass PJ, Weaver SC, Sabourin CL, Glenn AM, Klimstra W, Badorrek CS, Nasar F, Ward LA. Rusnak JM, et al. Viruses. 2019 Aug 31;11(9):807. doi: 10.3390/v11090807. Viruses. 2019. PMID: 31480472 Free PMC article.

3

Development of a highly sensitive in vitro endothelial cell toxicity assay for evaluating ricin toxin A chain-based vaccines or therapeutics.

Machesky NJ, Rusnak JM, Moore EH, Dorsey CB, Ward LA. Machesky NJ, et al. Among authors: rusnak jm. Toxicon. 2019 Sep;167:152-161. doi: 10.1016/j.toxicon.2019.06.015. Epub 2019 Jun 14. Toxicon. 2019. PMID: 31207351

4

Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.

Clarke DK, Xu R, Matassov D, Latham TE, Ota-Setlik A, Gerardi CS, Luckay A, Witko SE, Hermida L, Higgins T, Tremblay M, Sciotto-Brown S, Chen T, Egan MA, Rusnak JM, Ward LA, Eldridge JH. Clarke DK, et al. Among authors: rusnak jm. Lancet Infect Dis. 2020 Apr;20(4):455-466. doi: 10.1016/S1473-3099(19)30614-0. Epub 2020 Jan 14. Lancet Infect Dis. 2020. PMID: 31952923 Clinical Trial.

5

Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers.

Rusnak JM, Kortepeter MG, Hawley RJ, Anderson AO, Boudreau E, Eitzen E. Rusnak JM, et al. Biosecur Bioterror. 2004;2(4):281-93. doi: 10.1089/bsp.2004.2.281. Biosecur Bioterror. 2004. PMID: 15650438

6

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome.

Boudreau EF, Josleyn M, Ullman D, Fisher D, Dalrymple L, Sellers-Myers K, Loudon P, Rusnak J, Rivard R, Schmaljohn C, Hooper JW. Boudreau EF, et al. Vaccine. 2012 Mar 2;30(11):1951-8. doi: 10.1016/j.vaccine.2012.01.024. Epub 2012 Jan 14. Vaccine. 2012. PMID: 22248821 Clinical Trial.

7

Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

Rusnak JM, Kortepeter MG, Aldis J, Boudreau E. Rusnak JM, et al. J Occup Environ Med. 2004 Aug;46(8):801-11. doi: 10.1097/01.jom.0000135539.99691.4e. J Occup Environ Med. 2004. PMID: 15300132

8

Management guidelines for laboratory exposures to agents of bioterrorism.

Rusnak JM, Kortepeter MG, Hawley RJ, Boudreau E, Aldis J, Pittman PR. Rusnak JM, et al. J Occup Environ Med. 2004 Aug;46(8):791-800. doi: 10.1097/01.jom.0000135536.13097.8a. J Occup Environ Med. 2004. PMID: 15300131

9

Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.

Rusnak JM, Gibbs P, Boudreau E, Clizbe DP, Pittman P. Rusnak JM, et al. Vaccine. 2011 Apr 12;29(17):3222-9. doi: 10.1016/j.vaccine.2011.02.037. Epub 2011 Feb 26. Vaccine. 2011. PMID: 21354483

10

Laboratory exposures to staphylococcal enterotoxin B.

Rusnak JM, Kortepeter M, Ulrich R, Poli M, Boudreau E. Rusnak JM, et al. Emerg Infect Dis. 2004 Sep;10(9):1544-9. doi: 10.3201/eid1009.040250. Emerg Infect Dis. 2004. PMID: 15498154 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page